Clinical PsychometricsDepression ScalesPsychological Assessments

Beck Depression Inventory – Second Edition (BDI-II)

A comprehensive academic review of the Beck Depression Inventory – Second Edition (BDI-II), examining its psychometric properties, theoretical underpinnings, factorial validity, scoring conventions, and clinical utility.

memjavad
PUBLISHED
Scientifically Reviewed · Dr. Marwa Abd-Alazim · September 4, 2026
Medically & Scientifically Reviewed Verified: September 4, 2026
Dr. Marwa Abd-Alazim Ph.D.
Professor of Psychology • University of Kerbala
Review Criteria & Clinical Standards

This content undergoes rigorous scientific peer-review and medical editorial standards at Arab Psychology Network to ensure clinical accuracy, validity, and compliance with evidence-based guidelines from leading psychological and healthcare authorities (APA / WHO).

1. Abstract

The Beck Depression Inventory – Second Edition (BDI-II) represents one of the most extensively utilized, psychometrically rigorous self-report instruments designed to quantify the severity of depressive symptomatology in adults and adolescents aged 13 years and older. Developed by Aaron T. Beck, Robert A. Steer, and Gregory K. Brown in 1996, the BDI-II constitutes a substantial revision of the original 1961 BDI and its 1978 revision (BDI-IA), aligning item content directly with the diagnostic criteria for Major Depressive Disorder outlined in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), which remain concordant with current DSM-5 and DSM-5-TR standards. Comprising 21 items scored on a 4-point severity scale ranging from 0 to 3, the instrument yields a cumulative composite score from 0 to 63, categorized into minimal (0–13), mild (14–19), moderate (20–28), and severe (29–63) depression.

Extensive psychometric investigations across psychiatric, medical, and non-clinical populations have universally affirmed the instrument’s exemplary measurement precision. Internal consistency estimates routinely yield Cronbach’s alpha coefficients approximating α = .92 to .93 among clinical psychiatric outpatients and α = .89 to .91 among non-clinical college and community cohorts. Test-retest stability coefficients over one-week intervals consistently exceed r = .90, demonstrating exceptional measurement replicability. Factor-analytic investigations predominantly reveal a robust hierarchical or bifactor structure consisting of a broad general depression dimension underpinned by two correlated first-order factors: Cognitive-Affective and Somatic-Vegetative dimensions. The scale demonstrates robust convergent validity with clinician-rated scales such as the Hamilton Depression Rating Scale (HDRS) and other self-report indices including the Patient Health Questionnaire-9 (PHQ-9), alongside discriminant validity distinguishing depressive phenomena from generalized anxiety syndromes. Consequently, the BDI-II serves as a gold-standard psychometric benchmark in clinical assessment, epidemiological monitoring, and psychotherapeutic efficacy research.

2. Keywords

Beck Depression Inventory-II, BDI-II, depression assessment, psychometrics, depressive severity, cognitive theory of depression, major depressive disorder, self-report inventory, factor analysis, construct validity

3. Authors

The Beck Depression Inventory – Second Edition was developed by a team of prominent psychiatric and psychological researchers renowned for pioneering cognitive psychopathology and psychometric scale construction:

  • Aaron T. Beck, M.D. (1921–2021): Widely recognized as the father of Cognitive Therapy and Cognitive Behavior Therapy (CBT). Dr. Beck was University Professor Emeritus of Psychiatry at the Perelman School of Medicine, University of Pennsylvania, and the President Emeritus of the Beck Institute for Cognitive Behavior Therapy in Bala Cynwyd, Pennsylvania. His transformative formulations of the cognitive triad of depression fundamentally altered modern psychopathology, clinical psychiatric diagnosis, and empirical psychotherapy research.
  • Robert A. Steer, Ed.D. (1941–2018): Professor of Psychiatry at the School of Osteopathic Medicine, Rowan University (formerly the University of Medicine and Dentistry of New Jersey – UMDNJ). Dr. Steer was an internationally recognized psychometrician and biostatistician who co-authored numerous psychometric tests with Aaron T. Beck, including the Beck Anxiety Inventory (BAI), the Beck Hopelessness Scale (BHS), and the Beck Scale for Suicide Ideation (BSS).
  • Gregory K. Brown, Ph.D.: Research Associate Professor of Clinical Psychology in Psychiatry at the Perelman School of Medicine, University of Pennsylvania, and Director of the Penn Center for the Prevention of Suicide. Dr. Brown is a distinguished clinical psychologist and suicide prevention scholar who played an instrumental role in revising the operationalized diagnostic indicators and empirical standardization of the BDI-II.

4. Purpose

The primary purpose of the Beck Depression Inventory – Second Edition (BDI-II) is to deliver a standardized, cost-effective, and highly reliable self-administered assessment of the severity of subjective and behavioral depressive symptoms in psychiatric, medical, and community settings. While the original 1961 BDI was conceived to measure clinical depression severity according to consensus clinical consensus of that era, the rapid evolution of psychiatric nomenclature necessitated a substantial overhaul. The BDI-II was systematically developed to address the criteria for Major Depressive Episode specified in the DSM-IV, ensuring that symptom domains reflect modern empirical psychopathology. Critically, the instrument is designed not as a definitive standalone diagnostic instrument for diagnosing Major Depressive Disorder (which requires structured clinical interviewing, assessment of functional impairment, exclusion of medical or substance-induced etiologies, and evaluation of bipolar diathesis), but rather as an accurate quantitative dimensional measure of current symptom intensity.

In clinical practice, the BDI-II fulfills multiple vital operational functions:

  • Intake Screening and Severity Stratification: It provides intake clinicians with immediate baseline data regarding the depth of a patient’s affective disturbance, cognitive despair, and vegetative disruption, facilitating appropriate triage into outpatient, intensive outpatient, or acute inpatient levels of care.
  • Treatment Monitoring and Measurement-Based Care: Because the BDI-II captures symptoms experienced over the past two weeks, it serves as an optimal tool for measurement-based care (MBC). Administered at bi-weekly or monthly intervals, it offers clinicians precise longitudinal trajectories regarding treatment response, indicating whether pharmacotherapy, cognitive-behavioral interventions, or neurostimulation strategies are yielding clinically meaningful improvements or whether therapeutic regimens require timely augmentation.
  • Suicide Risk Screening: Item 9 specifically evaluates suicidal thoughts or wishes, moving systematically from absolute absence of ideation to explicit intent with available opportunity. In clinical triage, any endorsement above zero immediately triggers mandatory comprehensive suicide risk protocols, establishing the scale as an indispensable risk-management component.

In academic and clinical research contexts, the BDI-II functions as a primary or secondary outcome measure across randomized controlled trials (RCTs) assessing novel psychotropic agents, psychotherapeutic modalities, and psychiatric somatic treatments (e.g., transcranial magnetic stimulation, electroconvulsive therapy). Its granular score distribution enables researchers to determine effect sizes, continuous symptom reduction slopes, and categorical response rates (e.g., ≥50% reduction from baseline) or clinical remission cutoffs (scores ≤9 or ≤13 depending on trial parameters). Moreover, its application in large-scale epidemiological and neuropsychiatric studies allows cross-study harmonizations, establishing a universal metric across international clinical science.

5. Psychological Construct

The construct measured by the BDI-II is depressive symptom severity, characterized as a multifaceted, clinically heterogeneous syndrome encompassing emotional, cognitive, motivational, somatic, and neurovegetative dysfunctions. Unlike unifactorial conceptualizations of negative affect, contemporary psychopathology conceptualizes depression as a constellation of interacting biological, affective, and cognitive systems. The BDI-II addresses this complexity by operationalizing 21 specific symptom domains, systematically partitioned into distinct subcomponents:

Cognitive and Affective Dimension

This dimension reflects distorted information processing, negative valence evaluations, and emotional distress. It comprises:

  • Sadness (Item 1): Pervasive dysphoric mood, sorrow, and subjective psychic pain, ranging from absent distress to unbearable despair.
  • Pessimism (Item 2): Negative expectancies regarding the future, marked by hopelessness, belief in inevitable failure, and resignation that conditions cannot improve.
  • Past Failure (Item 3): Retrospective attributional bias, wherein personal history is interpreted solely through an unyielding lens of perceived underachievement, error, and personal inadequacy.
  • Loss of Pleasure (Item 4): Anhedonia, reflecting diminished consummatory and anticipatory reward processing across activities previously perceived as gratifying.
  • Guilty Feelings (Item 5): Excessive, irrational self-reproach and moral condemnation over perceived real or imagined wrongdoings, failings, or missed moral obligations.
  • Punishment Feelings (Item 6): Dysfunctional cognitive appraisals regarding personal culpability, characterized by pervasive dread, expectations of retributive suffering, or feeling actively condemned.
  • Self-Dislike (Item 7): Deep-seated collapse of self-esteem, self-rejection, and intense feelings of disappointment directed inward.
  • Self-Criticalness (Item 8): Pervasive internal hyper-scrutiny, rigid self-blaming attributions, and assigning total personal fault for adverse external outcomes.
  • Suicidal Thoughts or Wishes (Item 9): Progressive emergence of passive death wishes, active suicidal ideation, and acute intent to terminate one’s life.
  • Worthlessness (Item 14): Profound subjective loss of perceived personal utility, value, or social relevance, progressing to complete existential insignificance.

Somatic and Vegetative Dimension

This dimension evaluates the physiological disruption, neuroendocrine alterations, and bodily depletion characteristic of mood disorders:

  • Crying (Item 10): Affective lability, hypersensitivity, or in its most severe manifestation, the complete inability to weep despite desperate emotional agony.
  • Agitation (Item 11): Psychomotor agitation, inner restlessness, and physiological inability to remain physically still, reflecting noradrenergic and dopaminergic dysregulation.
  • Loss of Interest (Item 12): Social and occupational withdrawal, representing motivational deficits and progressive disconnection from external human interaction.
  • Indecisiveness (Item 13): Executive cognitive dysfunction manifested as paralysis in everyday cognitive choices, ambivalence, and delayed decision processing.
  • Loss of Energy (Item 15): Anergia, subjective depletion of vitality, and significant effort required to initiate or sustain basic goal-directed behaviors.
  • Changes in Sleeping Pattern (Item 16): Bidirectional disruption in circadian and sleep architecture, capturing both classic sleep-maintenance/terminal insomnia and atypical hypersomnia.
  • Irritability (Item 17): Diminished frustration tolerance, affective impatience, and subjective interpersonal volatility.
  • Changes in Appetite (Item 18): Bidirectional metabolic dysregulation, capturing marked hypophagia/anorexia or atypical hyperphagia/carbohydrate craving.
  • Concentration Difficulty (Item 19): Disruption in sustained attention, working memory capacity, and mental focus during everyday intellectual tasks.
  • Tiredness or Fatigue (Item 20): Chronic physiological exhaustion, low physical stamina, and feeling drained by minimal somatic exertion.
  • Loss of Interest in Sex (Item 21): Hypoactive sexual desire, marked reduction in libido, and sexual anhedonia.

6. Theoretical Framework

The architectural underpinning of the BDI-II is grounded in Aaron T. Beck’s cognitive model of psychopathology. Developed in the early 1960s as a departure from traditional psychoanalytic perspectives on depression (which posited retroflected hostility or inward anger), Beck’s model posits that the fundamental pathogenesis of depressive syndromes lies in hyper-activated negative cognitive structures rather than primary affective disruptions.

The Cognitive Triad

Central to Beck’s formulation is the Cognitive Triad, a constellation of pervasive, automatic, and systematically distorted cognitive evaluations regarding:

  1. The Self: The individual perceives themselves as inherently defective, inadequate, diseased, or unlovable. Items measuring self-dislike, past failure, self-criticalness, and worthlessness capture this dimension.
  2. The World / Present Experiences: Current life occurrences are interpreted as unremittingly demanding, hostile, and filled with insurmountable barriers. Items measuring loss of pleasure, guilt, and loss of interest reflect this framework.
  3. The Future: The individual anticipates endless hardship, frustration, and failure, concluding that conditions will never improve. The pessimism and suicidal ideation items directly operationalize this systemic hopelessness.

Depressive Schemas and Cognitive Vulnerability

According to Beckian theory, individuals prone to depression harbor latent, enduring cognitive schemas—mental templates organized from adverse developmental, familial, or interpersonal experiences. During periods of environmental quiescence, these schemas remain dormant. However, when triggered by congruent life stressors (e.g., loss of a significant relationship, interpersonal rejection, occupational setback), these maladaptive schemas become hyper-accessible, overriding more balanced, reality-based processing pathways.

Once operational, these schemas systematically skew information processing through cognitive distortions, such as arbitrary inference, selective abstraction, overgeneralization, and dichotomous (all-or-nothing) thinking. Consequently, the individual misinterprets neutral or ambiguous environmental stimuli as definitive proof of inadequacy. The somatic and vegetative sequelae evaluated by the BDI-II (e.g., sleep disturbance, appetite changes, severe anergia) are understood within this cognitive framework as biological and behavioral cascades directly downstream from prolonged negative affective activation, neuroendocrine stress response activation (e.g., hypothalamic-pituitary-adrenal [HPA] axis dysregulation), and behavioral withdrawal.

Alignment with Diagnostic Nosology (DSM-IV through DSM-5-TR)

While the original 1961 BDI reflected clinical observations of psychoanalytically treated psychiatric inpatients, the BDI-II was intentionally recalibrated to operationalize the diagnostic criteria for Major Depressive Episode within the DSM-IV framework. To achieve full structural and content parity, several critical updates were integrated:

  • Timeframe Expansion: The symptom recall window was extended from “the past week including today” (BDI-IA) to “the past two weeks including today” (BDI-II), directly matching the DSM requirement that symptoms must persist for at least two weeks for a major depressive episode diagnosis.
  • Item Substitution and Modernization: Four items from the original BDI were retired due to poor discriminant performance: Body Image Change, Work Difficulty, Somatic Preoccupation, and Weight Loss. These were replaced by four items with greater diagnostic precision: Agitation, Worthlessness, Concentration Difficulty, and Loss of Energy.
  • Bidirectional Scoring for Neurovegetative Disturbances: The BDI-II explicitly integrated bidirectional response choices for changes in sleeping patterns (Item 16) and changes in appetite (Item 18), allowing the scale to register both melancholic vegetative features (insomnia, anorexia) and atypical neurovegetative presentations (hypersomnia, hyperphagia).

7. Validity

The psychometric validity of the BDI-II has been thoroughly established through multi-site investigations across international psychiatric cohorts, general hospital patients, and diverse community samples.

Construct and Convergent Validity

Convergent validity demonstrates that the BDI-II strongly correlates with other validated instruments measuring depressive constructs. In their seminal validation study, Beck, Steer, and Brown (1996) reported a substantial Pearson correlation between the BDI-II and the Hamilton Rating Scale for Depression (HDRS-17) of r = .71 among psychiatric outpatients. Subsequent studies consistently replicate high-magnitude correlations ranging between r = .68 and .84. Similar strong relationships are observed with other self-report measures:

  • Patient Health Questionnaire (PHQ-9): Empirical correlations consistently range from r = .79 to .86 across both primary care and outpatient psychiatric settings, confirming that these instruments measure a shared underlying construct.
  • Center for Epidemiologic Studies Depression Scale (CES-D): Correlations routinely exceed r = .80 in non-clinical adolescent and university populations.
  • Montgomery-Åsberg Depression Rating Scale (MADRS): Clinician ratings correlate with BDI-II scores between r = .70 and .78 in clinical trials.

Discriminant Validity

Discriminant validity involves demonstrating that the BDI-II assesses depression rather than adjacent but distinct affective phenomena, such as generalized anxiety. When evaluated alongside the Beck Anxiety Inventory (BAI), the BDI-II typically correlates between r = .45 and .60. While these coefficients reflect the real-world clinical comorbidity of anxious and depressive symptoms (shared negative affectivity), exploratory and confirmatory factor analyses show that items from the BDI-II and BAI reliably load onto distinct latent constructs without significant cross-loading. Furthermore, when compared with measures of somatic disease severity (e.g., physical disability scales, systemic inflammation biomarkers), BDI-II scores demonstrate divergent validity, confirming that the scale assesses clinical depression rather than general physical illness.

Criterion and Predictive Validity

Receiver Operating Characteristic (ROC) curves confirm the BDI-II’s diagnostic utility in screening for Major Depressive Episodes confirmed by the Structured Clinical Interview for DSM (SCID). In clinical outpatient samples, using a threshold score of ≥14 yields a sensitivity of approximately 92% to 94% and a specificity of 85% to 89%. For identifying moderate-to-severe depression (scores ≥20), specificities consistently exceed 90%. Moreover, longitudinal investigations have documented that baseline BDI-II scores prospectively predict critical clinical endpoints, including treatment non-adherence, relapse rates, and prospective engagement in non-suicidal self-injury and suicide attempts.

8. Reliability

The Beck Depression Inventory – Second Edition exhibits exceptional psychometric reliability across diverse populations, clinical settings, and linguistic adaptations.

Internal Consistency

The internal consistency of the BDI-II, measured via Cronbach’s alpha (α), consistently ranks among the highest reported for clinical self-report inventories:

  • Psychiatric Outpatient Samples: In the initial standardization sample of 500 clinical outpatients (Beck et al., 1996), the inventory demonstrated an overall internal consistency of α = .92. Subsequent clinical replication studies globally have reported values ranging between α = .91 and .94.
  • Non-Clinical / College Student Cohorts: In the original standardization cohort of 120 college undergraduates, the alpha coefficient was α = .93. Subsequent meta-analyses synthesizing non-clinical samples have established an average internal consistency of α = .89 (95% CI [.88, .91]).
  • Medical Populations: Across patients diagnosed with conditions such as chronic pain, cancer, coronary artery disease, multiple sclerosis, and stroke, internal consistency remains robust, typically falling between α = .87 and .92.

Item-total correlations further support the scale’s cohesion: nearly all 21 items display corrected item-total correlations exceeding r = .45, with key cognitive items (e.g., Loss of Pleasure, Sadness, Worthlessness) frequently demonstrating item-total correlations ranging from .60 to .75.

Test-Retest Reliability

Evaluating test-retest reliability requires balancing measurement stability with the natural clinical fluctuations of depressive states. In a subset of 26 psychiatric outpatients re-evaluated over a one-week interval between clinical therapy intake visits, Beck et al. (1996) reported a test-retest correlation of r = .93 (p < .001). Paired t-tests indicated no statistically significant difference between scores across the two assessment points, indicating strong stability in the absence of therapeutic intervention. In non-clinical collegiate cohorts, one-to-two-week test-retest intervals regularly generate coefficients ranging from r = .78 to .88, with variations largely reflecting mild transient mood changes.

9. Factor Analysis

The latent dimensionality of the BDI-II has been investigated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA). Across thousands of participants in varied demographic and psychiatric populations, structural analyses consistently support a multidimensional, hierarchical construct.

Exploratory Factor Analytic Findings

Initial principal factor analyses with Promax and Varimax rotations conducted by Beck et al. (1996) revealed that the 21 items are best characterized by two correlated first-order factors:

  • Cognitive-Affective Factor: This factor captures items reflecting psychological distress, negative self-evaluations, and dysphoria. Salient primary loadings include: Sadness (1), Pessimism (2), Past Failure (3), Loss of Pleasure (4), Guilty Feelings (5), Punishment Feelings (6), Self-Dislike (7), Self-Criticalness (8), Suicidal Thoughts (9), Indecisiveness (13), and Worthlessness (14).
  • Somatic-Vegetative Factor: This factor accounts for physical and physiological manifestations. Salient loadings include: Loss of Energy (15), Changes in Sleeping Pattern (16), Irritability (17), Changes in Appetite (18), Concentration Difficulty (19), Tiredness or Fatigue (20), and Loss of Interest in Sex (21).

Certain items, such as Crying (Item 10) and Loss of Interest (Item 12), periodically exhibit secondary cross-loadings, as anhedonia and crying behaviors straddle emotional and neurobiological processing.

Confirmatory Factor Analysis and Bifactor Modeling

Subsequent modern CFA studies have rigorously tested competing structural configurations, including single-factor models, two-factor correlated models, three-factor models (splitting Cognitive, Affective, and Somatic components), and bifactor architectures. Compelling statistical support frequently favors a Bifactor Model (or a second-order hierarchical model), wherein a single overarching “General Depression” factor accounts for the vast majority of common variance (often between 65% and 80%), while two independent specific group factors (Cognitive-Affective and Somatic-Vegetative) capture residual domain-specific covariance.

Structural fit indices reported in large clinical populations consistently confirm strong model fit for the bifactor representation:

  • Comparative Fit Index (CFI): Routinely > .95
  • Tucker-Lewis Index (TLI): Routinely > .94
  • Root Mean Square Error of Approximation (RMSEA): Values typically range between .038 and .054, with 90% confidence intervals well below the .06 benchmark for good fit.
  • Standardized Root Mean Square Residual (SRMR): Consistently ≤ .045.

These bifactor findings provide clear psychometric justification for calculating and interpreting a single composite total score (representing the general depression dimension), while concurrently confirming that granular subscale scoring may provide supplemental clinical insights in specialized neuropsychiatric or psychosomatic contexts.

10. Instrument / Measurement Tool

The technical parameters, administrative architecture, and clinical scoring guidelines of the BDI-II are summarized below:

  • Test Type: Standardized self-report inventory / psychological rating scale.
  • Administration Format: Paper-and-pencil questionnaire, supervised clinical digital administration, or standardized computerized testing software.
  • Target Population: Adolescents and adults aged 13 to 80+ years.
  • Reading Level: Fifth-grade reading level, ensuring accessible comprehension across diverse educational backgrounds.
  • Completion Time: Approximately 5 to 10 minutes (slightly extended in patients exhibiting severe psychomotor retardation or executive dysfunction).
  • Item Count: 21 items, each corresponding to a specific symptom cluster.
  • Response Scale: 4-point severity scale from 0 to 3 for each item symptom group. Each item provides four graded statements arranged in ascending clinical severity, with numerical weights from 0 (symptom absent or unimpaired) to 3 (severe, incapacitating symptom level). Two items (Item 16: Changes in Sleeping Pattern, and Item 18: Changes in Appetite) offer split choices at levels 1, 2, and 3 (e.g., 1a vs. 1b) to capture bidirectional shifts (e.g., sleeping more vs. sleeping less), each carrying identical numeric weight.
  • Scoring Rules:
    • The administrator verifies that only one option is chosen per item; if a respondent circles multiple options within a single item, the option with the highest numerical value is recorded.
    • The overall score is computed by summing the ratings across all 21 items, resulting in a continuous total score ranging from 0 to 63.
    • No items are reverse-scored; every item contributes positively to the severity score.
    • If more than two items are left completely blank, the inventory is technically invalid and should not be formally scored without clinical follow-up. When one or two items are omitted, some clinical protocols prorate the total score based on the mean of the completed items, though conservative practice recommends directly querying the missing items with the patient.
  • Standard Cutoff Score Interpretations:
    • 0 – 13: Minimal depression (typical non-clinical fluctuation)
    • 14 – 19: Mild depression
    • 20 – 28: Moderate depression
    • 29 – 63: Severe depression
  • Critical Action Flags: An endorsement of ≥1 on Item 9 (Suicidal Thoughts or Wishes) indicates positive suicide risk and mandates immediate comprehensive clinical risk evaluation and diagnostic assessment.

11. Permissions & Fee and Test Year

The Beck Depression Inventory – Second Edition was published in its definitive standardized form in 1996 by The Psychological Corporation (now integrated into Pearson Clinical Assessment). The instrument is a fully copyrighted, commercially licensed psychometric tool. It is not in the public domain and cannot be distributed, republished, reproduced, or digitized without prior formal authorization from the copyright holder.

Clinical practitioners, hospitals, and independent researchers must purchase legitimate testing forms, digital administration tokens, or licensing agreements through Pearson Clinical Assessment. A standard per-administration or test-manual fee applies. For funded academic or non-commercial clinical research trials, formal research licensing permissions must be secured directly via Pearson’s Global Rights and Permissions division. Academic institutions frequently acquire institutional clinical licenses for training clinics and authorized university research centers.

12. References

The following peer-reviewed publications and clinical manuals document the historical development, structural standardization, and empirical psychometrics of the BDI-II:

  • American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). American Psychiatric Association.
  • American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
  • Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4(6), 561–571. https://doi.org/10.1001/archpsyc.1961.01710120031004
  • Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the Beck Depression Inventory–II. Psychological Corporation.
  • Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996). Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. Journal of Personality Assessment, 67(3), 588–597. https://doi.org/10.1207/s15327752jpa6703_13
  • Brouwer, D., Meijer, R. R., & Zevalkink, J. (2013). On the factor structure of the Beck Depression Inventory-II: Validation, calibration, and measurement invariance in a large Dutch sample. Psychological Assessment, 25(1), 136–147. https://doi.org/10.1037/a0029707
  • Dozois, D. J., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck Depression Inventory–II. Psychological Assessment, 10(2), 83–89. https://doi.org/10.1037/1040-3590.10.2.83
  • Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
  • Steer, R. A., Ball, R., Ranieri, W. F., & Beck, A. T. (1999). Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. Journal of Clinical Psychology, 55(1), 117–128. https://doi.org/10.1037/a0037380
  • Wang, Y. P., & Gorenstein, C. (2013). Psychometric properties of the Beck Depression Inventory-II: A comprehensive review. Revista Brasileira de Psiquiatria, 35(4), 416–431. https://doi.org/10.1590/1516-4446-2012-1048

13. Items of the Scale (Questionnaire)

Below are the authentic scale items in their original language as published in the standard psychometric validation studies, without modification or translation to preserve instrument validity and reliability:
Instructions / Directions: This questionnaire consists of 21 groups of statements. Please read each group of statements carefully, and then pick out the one statement in each group that best describes the way you have been feeling during the past two weeks, including today. Circle the number beside the statement you have picked. If several statements in the group seem to apply to you equally well, circle the highest number for that group. Be sure that you do not choose more than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 (Changes in Appetite).
Response Scale: 4-point severity scale from 0 to 3 for each item symptom group
Scoring / Reverse Items: Items are rated from 0 to 3. Total score is obtained by summing the ratings across all 21 items (range 0–63). Cutoffs typically used: 0–13 minimal depression, 14–19 mild depression, 20–28 moderate depression, 29–63 severe depression.
1

Sadness (0 = I do not feel sad; 1 = I feel sad much of the time; 2 = I am sad all the time; 3 = I am so sad or unhappy that I can't stand it)
2

Pessimism (0 = I am not discouraged about my future; 1 = I feel more discouraged about my future than I used to be; 2 = I do not expect things to work out for me; 3 = I feel my future is hopeless and will only get worse)
3

Past Failure (0 = I do not feel like a failure; 1 = I have failed more than I should have; 2 = As I look back, I see a lot of failures; 3 = I feel I am a total failure as a person)
4

Loss of Pleasure (0 = I get as much pleasure as I ever did from the things I enjoy; 1 = I don't enjoy things as much as I used to; 2 = I get very little pleasure from the things I used to enjoy; 3 = I can't get any pleasure from the things I used to enjoy)
5

Guilty Feelings (0 = I don't feel particularly guilty; 1 = I feel guilty over many things I have done or should have done; 2 = I feel quite guilty most of the time; 3 = I feel guilty all of the time)
6

Punishment Feelings (0 = I don't feel I am being punished; 1 = I feel I may be punished; 2 = I expect to be punished; 3 = I feel I am being punished)
7

Self-Dislike (0 = I feel the same about myself as ever; 1 = I have lost confidence in myself; 2 = I am disappointed in myself; 3 = I dislike myself)
8

Self-Criticalness (0 = I don't criticize or blame myself more than usual; 1 = I am more critical of myself than I used to be; 2 = I criticize myself for all of my faults; 3 = I blame myself for everything bad that happens)
9

Suicidal Thoughts or Wishes (0 = I don't have any thoughts of killing myself; 1 = I have thoughts of killing myself, but I would not carry them out; 2 = I would like to kill myself; 3 = I would kill myself if I had the chance)
10

Crying (0 = I don't cry anymore than I used to; 1 = I cry more than I used to; 2 = I cry over every little thing; 3 = I feel like crying, but I can't)
11

Agitation (0 = I am no more restless or wound up than usual; 1 = I feel more restless or wound up than usual; 2 = I am so restless or agitated that it's hard to stay still; 3 = I am so restless or agitated that I have to keep moving or doing something)
12

Loss of Interest (0 = I have not lost interest in other people or activities; 1 = I am less interested in other people or things than before; 2 = I have lost most of my interest in other people or things; 3 = It's hard to get interested in anything)
13

Indecisiveness (0 = I make decisions about as well as ever; 1 = I find it more difficult to make decisions than usual; 2 = I have much greater difficulty in making decisions than I used to; 3 = I have trouble making any decisions)
14

Worthlessness (0 = I do not feel I am worthless; 1 = I don't consider myself as worthwhile and useful as I used to; 2 = I feel more worthless as compared to other people; 3 = I feel utterly worthless)
15

Loss of Energy (0 = I have as much energy as ever; 1 = I have less energy than I used to have; 2 = I don't have enough energy to do very much; 3 = I don't have enough energy to do anything)
16

Changes in Sleeping Pattern (0 = I have not experienced any change in my sleeping pattern; 1a = I sleep somewhat more than usual; 1b = I sleep somewhat less than usual; 2a = I sleep a lot more than usual; 2b = I sleep a lot less than usual; 3a = I sleep most of the day; 3b = I wake up 1-2 hours early and can't get back to sleep)
17

Irritability (0 = I am no more irritable than usual; 1 = I am more irritable than usual; 2 = I am much more irritable than usual; 3 = I am irritable all the time)
18

Changes in Appetite (0 = I have not experienced any change in my appetite; 1a = My appetite is somewhat less than usual; 1b = My appetite is somewhat greater than usual; 2a = My appetite is much less than before; 2b = My appetite is much greater than usual; 3a = I have no appetite at all; 3b = I crave food all the time)
19

Concentration Difficulty (0 = I can concentrate as well as ever; 1 = I can't concentrate as well as usual; 2 = It's hard to keep my mind on anything for very long; 3 = I find I can't concentrate on anything)
20

Tiredness or Fatigue (0 = I am no more tired or fatigued than usual; 1 = I get more tired or fatigued more easily than usual; 2 = I am too tired or fatigued to do a lot of the things I used to do; 3 = I am too tired or fatigued to do most of the things I used to do)
21

Loss of Interest in Sex (0 = I have not noticed any recent change in my interest in sex; 1 = I am less interested in sex than I used to be; 2 = I am much less interested in sex now; 3 = I have lost interest in sex completely)
★

Rate This Scale

5.0 / 5 • 1 vote

Cite This Article

memjavad (2026, September 4). Beck Depression Inventory – Second Edition (BDI-II). PSYCHOLOGICAL DATABASE. https://en.arabpsychology.com/scales/beck-depression-inventory-second-edition-bdi-ii-2/
memjavad. “Beck Depression Inventory – Second Edition (BDI-II).” PSYCHOLOGICAL DATABASE, 4 September 2026, https://en.arabpsychology.com/scales/beck-depression-inventory-second-edition-bdi-ii-2/.
memjavad. “Beck Depression Inventory – Second Edition (BDI-II).” PSYCHOLOGICAL DATABASE. September 4, 2026. https://en.arabpsychology.com/scales/beck-depression-inventory-second-edition-bdi-ii-2/.